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Abstract
Background: Diabetes is associated with a cardiomyopathy that is independent of coronary artery
disease or hypertension. In the present study we used in vivo magnetic resonance imaging (MRI) and
echocardiographic techniques to examine and characterize early changes in myocardial function in a mouse
model of type 1 diabetes.
Methods: Diabetes was induced in 8-week old C57BL/6 mice with two intraperitoneal injections of
streptozotocin. The blood glucose levels were maintained at 19–25 mmol/l using intermittent low dosages
of long acting insulin glargine. MRI and echocardiography were performed at 4 weeks of diabetes (age of
12 weeks) in diabetic mice and age-matched controls.
Results: After 4 weeks of hyperglycemia one marker of mitochondrial function, NADH oxidase activity,
was decreased to 50% of control animals. MRI studies of diabetic mice at 4 weeks demonstrated significant
deficits in myocardial morphology and functionality including: a decreased left ventricular (LV) wall
thickness, an increased LV end-systolic diameter and volume, a diminished LV ejection fraction and cardiac
output, a decreased LV circumferential shortening, and decreased LV peak ejection and filling rates. M-
mode echocardiographic and Doppler flow studies of diabetic mice at 4 weeks showed a decreased wall
thickening and increased E/A ratio, supporting both systolic and diastolic dysfunction.
Conclusion:  Our study demonstrates that MRI interrogation can identify the onset of diabetic
cardiomyopathy in mice with its impaired functional capacity and altered morphology. The MRI technique
will lend itself to repetitive study of early changes in cardiac function in small animal models of diabetic
cardiomyopathy.
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Background
The existence of diabetic cardiomyopathy, a myocardial
disease associated with diabetes in the absence of coro-
nary artery disease, hypertension or any other known car-
diac disease, is supported by evidence accumulated from
a large and expanding literature [1-4]. Abnormalities in
cardiac function and structure in diabetic subjects have
been demonstrated in animal [5-8] and human studies [9-
12]. The pathogenesis of this ventricular dysfunction
remains unknown, but includes impaired metabolism,
myocardial fibrosis, small vessel disease and autonomic
neuropathy [1-4].
Mice are increasingly used in diabetes research mainly
because of the ability to create genetically engineered mice
for investigation of the molecular mechanisms underlying
cardiovascular complications [13-19]. Chemical induc-
tion of insulin deficiency by a cytotoxic agent for pancre-
atic beta cells, streptozotocin (STZ), produces a well-
characterized model of type 1 diabetes [20]. This model
allows more accurate timing of selected metabolic events
and correlation with their pathophysiologic conse-
quences. Assessment of cardiac function in mouse models
of both type 1 and type 2 diabetes has relied on conven-
tional echocardiography [15-17,19], invasive in vivo cath-
eterization [18,19,21], or ex vivo [14,22,23] techniques
with their associated restrictions upon accuracy or serial
studies in timed experiments. The noninvasive magnetic
resonance imaging (MRI) techniques provide a 3-dimen-
sional representation of cardiac structure and function,
and have proven to be a reliable and reproducible means
of studying in vivo cardiac morphology and function in
mice under physiological conditions [24-28]. Only
recently, the use of cardiac MRI has been reported for
assessment of the cardiomyopathic changes in type 2 dia-
betic mice [29].
The purpose of the present study was to use MRI tech-
niques to examine the early onset of myocardial dysfunc-
tion in STZ-induced diabetic mice. These studies can then
be applied to interventions that may alter or prevent the
onset of this condition using the advantage of repetitive
examinations over selected periods of time.
Methods
Mice
6–8 week old C57BL/6 female mice were obtained from
Harlan (Indianapolis, IN) and housed at the MRI animal
facility. All animals had free access to standard laboratory
chow and water. Animal protocols were approved by the
local Institutional Animal Care and Use Committee.
Induction of diabetes
Mice were injected intraperitoneally with 100 mg/kg of
STZ (in 0.05 mol/l citrate buffer, pH 4.5, Sigma, St. Louis,
MO) or vehicle once a day for two consecutive days. Tail
blood glucose (TBG) levels were measured using a glucose
oxidase test strip (Lifescan, Milpitas, CA). Animals were
considered to be diabetic if their TBG is > 13 mmol/l. The
blood glucose levels and body weight of all mice were
monitored biweekly. When their TBG is > 22 mmol/l, they
were given intermittent low dosages of long acting insulin
glargine [30] to maintain blood glucose at 19–25 mmol/
l. Mitochondrial NADH oxidase activity was determined
in ventricular tissues from diabetic mice, and MRI studies
were performed on diabetic mice at 4 weeks. Age matched
controls were included for comparisons.
Mouse preparation
For MRI studies, mice were anesthetized with inhaled iso-
flurane (1.5% at 1 L/min oxygen flow) via a nose cone.
During the experiment, the mouse was positioned supine
on a nonmagnetic warming pad to maintain constant
body temperature throughout the MR study.
In vivo MRI
Experiments were performed on a 7 Tesla MR scanner
(Bruker BioSpin, Ettlingen, Germany). For cardiac imag-
ing the gradient echo sequence [31] with te = 4.0 ms, tr =
100 ms, and a flip angle, θ = 85°–90° was used for all
experiments. The heart was initially positioned by meas-
urement to the center of the magnet and then further set
by observing the position using fast imaging with steady
state precession (FISP) [32] as the animal was moved.
Once the heart was in the iso-center a gradient echo
sequence with te = 4.0 ms and tr = 50 ms was used to
acquire single slice images in all three (axial, sagittal and
coronal) planes. The slice position for the cine was set
using this pilot scan. For cine and volume imaging a field
of view, FOV = 2.56 × 2.56 cm was chosen and 256 each
of phase encode and read steps were used to resolve the
spatial distribution of excited spins. The image was made
after zero filling in each direction to 512 × 512. Window
functions were not used and some minor image quality
enhancement may be achieved if window functions are
used. For our purpose the signal contrast of the myocar-
dium and "white" blood was sufficient to allow calcula-
tion of the relevant parameters.
Spectrometer triggering with combined respiratory and
ECG triggers was used in all experiments. Thus, all MRI
data are adjusted to accommodate for rate changes and
the data are reflective of the ambient cardiac function and
rate. The cardiac period, P, of mice used in these studies
ranged from ~120–180 ms, and a respiratory rate of ~18–
30 bpm. Trigger delays, td, were incremented at the spec-Cardiovascular Diabetology 2007, 6:6 http://www.cardiab.com/content/6/1/6
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trometer hardware in a chosen number of steps, nsteps,
(nsteps = 10) according to td = (P-(P/nsteps))/P, where period
is the time between the peaks of the R wave in the ECG
trace. The images at each increment of the period were
combined and displayed by cine in the mid-ventricular
short axis slice. These provided data for assessment of left
ventricular (LV) systolic and diastolic dynamics, and for
calculations of fractional circumferential shortening and
wall thickening after measuring the endocardial circum-
ferential length and myocardial wall thickness at end dias-
tole and end systole.
For volume calculations, a new set of images were col-
lected with the slice position advanced by the slice thick-
ness of 1.0 mm. In order to reduce the time that multi-
slice experiments fit in to the repetition time (Tr) used for
single slice experiments, the slice thickness was increased
to 1.25 mm. Thus, in this case, the resolution in the slice
shifting is compromised by 0.25 mm at most, and con-
tributes an error of about 0.1% in total volume calcula-
tions compared with a 1 mm slice thickness. The total
blood volume at end diastole and end systole was esti-
mated by taking the sum of all cavity slice volumes assum-
ing a uniform thickness of excitation across a chosen slice
at the two trigger points.
MRI analysis
For LV blood volume measurements, endocardial borders
were manually delineated. An independent observer was
used whenever a questionable or indistinct image was
encountered. These measurements rarely changed the
summed data obtained from a given data acquisition. The
end-diastolic volume (EDV) and end-systolic volume
(ESV) were calculated as the sum of all cavity slice vol-
umes at end diastole and end systole. For assessment of LV
systolic and diastolic dynamics, the cavity slice volume
was measured in all acquired images and was plotted
against the time from onset of the QRS trigger, and a vol-
ume-time curve was established. Peak ejection rate and
peak filling rate were calculated from the maximum
slopes of the LV ejection and filling curve [33].
Echocardiography
M-mode/Doppler echocardiography was performed using
a 13 MHz 15L8 probe and an Acuson Sequoia 256
echocardiography system (Acuson, Mountain View, CA).
The wall and cavity dimensions during diastole and sys-
tole were determined from long-axis views of the left ven-
tricle [34]. The mitral flow velocities were assessed by
Doppler, and the E wave and A wave were measured to
provide an estimate of diastolic function [35].
Mitochondrial function
Frozen and thawed mitoplasts from hearts were diluted
into 10 mmol/l 3-(N-morpholino)propane-sulfonic acid
(MOPS), 25 mmol/l KCl at pH 7.4 to a final concentration
of 50 µg/ml [36]. NADH oxidase activity was measured as
the rate of NADH disappearance at 340 nm upon addition
200 µM NADH [36]. Citrate synthase activity was moni-
tored by detection of 5,5'-dithiobis(2-nitrobenzoic acid)
(DTNB) reactive CoASH (412 nm, ε = 13,600) upon addi-
tion of 0.1 mmol/l DTNB, 0.3 mmol/l acetyl CoA, and 0.5
mmol/l oxaloacetate to frozen and thawed mitoplasts (20
µg/ml) [37]. All enzyme assays were performed at room
temperature.
Statistical analysis
Data are expressed as mean ± SEM. An unpaired 2-tailed
Student t  test was used to make comparisons between
control and diabetic groups. Significance was ascribed to
P values < 0.05.
Results
Effects of STZ on blood glucose and body weight
The mice generally developed significant elevation of
blood glucose within a week following STZ injection (Fig-
ure 1). The STZ-treated mice showed blood glucose levels
ranging from 17 to over 27 mmol/l as compared with 5.5–
8.3 mmol/l for citrate-treated control mice. Diabetic mice
with blood glucose levels of > 22 mmol/l were given low
dosages of long acting insulin (1–1.5 IU s.c.) daily to
maintain their blood glucose at 19–25 mmol/l. After 4
weeks of diabetes, the diabetic mice had a 13% lower
body weight and an 11% lower heart weight than non-
diabetic control mice. The ratio of heart weight to body
weight was not significantly changed (Table 1).
Myocardial morphology and function in diabetic mice
The animals tolerated the anesthesia and procedure with-
out difficulty. There were no post study deaths. The fast-
gradient echo MR technique provides sufficient contrast
between blood and myocardium to allow clear delinea-
tion of epicardial and endocardial borders (Figure 2). LV
diameters and wall thickness were measured in mid-ven-
tricular short-axis slices at end diastole and end systole.
After 4 weeks of diabetes, no significant change of endo-
cardial diameters at end diastole was observed (3.6 ± 0.1
vs. 3.4 ± 0.1 mm). However, endocardial diameters were
significantly increased at end systole (2.4 ± 0.1 vs. 1.8 ±
0.1 mm, P < 0.001). Diabetic mice also showed significant
thinning of the LV wall compared to control animals both
at end diastole (0.85 ± 0.03 vs. 1.01 ± 0.05 mm, P < 0.01)
and at end systole (1.19 ± 0.05 vs. 1.51 ± 0.06 mm, P <
0.001) (Table 2 & Figure 2).Cardiovascular Diabetology 2007, 6:6 http://www.cardiab.com/content/6/1/6
Page 4 of 8
(page number not for citation purposes)
The heart rates were similar between diabetic and control
mice (446 ± 11 vs. 470 ± 11 bpm). To determine the
effects of diabetes on LV systolic function, the LV blood
volumes were measured from multiple short-axis slices
that cover the whole heart at end diastole and end systole.
The EDV was not significantly changed after 4 weeks of
diabetes (44.8 ± 1.0 vs. 46.0 ± 1.1 µl). The ESV, on the
other hand, was increased by 23%. Therefore, a signifi-
cantly reduced myocardial contractile function was
observed in diabetic mice. The stroke volume, ejection
fraction and cardiac output were decreased by 20%, 18%
and 16%, respectively. A similar decrease in LV fractional
circumferential shortening was also seen in diabetic mice
(Table 3).
To assess LV systolic and diastolic dynamics, peak ejection
rate and peak filling rate were calculated from the systolic
and diastolic limbs of the volume-time curve (Figure 3).
In diabetic mice compared to controls, there was a signif-
icantly reduced maximum LV ejection rate (47 ± 5 vs. 62
± 3 µl/s, n = 8, P < 0.05) and filling rate (33 ± 4 vs. 49 ± 3
µl/s, n = 8, P < 0.01) indicating a decrease of both contrac-
tion and relaxation (Figures 3 &4).
To compare the MRI techniques with conventional
echocardiography, M-mode echocardiographic and Dop-
pler flow studies were performed on control and 4-wk
STZ-diabetic mice. The diabetic mice showed a decreased
wall thickening and increased E/A ratio, indicating that
STZ-induced diabetes affects both systolic and diastolic
function (Figure 5).
Effect of diabetes on mitochondrial NADH oxidase and 
citrate synthase activity
To begin to assess the effects of diabetes on mitochondrial
function, NADH oxidase activity, a measure of overall
electron transport, was determined in mitoplasts prepared
from hearts isolated from control and diabetic (4 weeks)
mice. As shown in Figure 6, diabetes resulted in a decline
in NADH oxidase activity of approximately 50% relative
to control values. This was not due to an overall decline in
mitochondrial protein content given that the yield of
mitoplasts (not shown) and the activity of the Krebs cycle
enzyme citrate synthase (Figure 6) did not vary between
control and diabetic hearts. Therefore, this parameter of
mitochondrial electron transport activity was severely
compromised within 4 weeks of the onset of marked
hyperglycemia. In contrast to the nearly 50% decline in
cardiac NADH-linked electron transport chain activity
(NADH oxidase) induced by diabetes, complex I activity
declined 21.2% (P value ≤ 0.003). Complex I is the rate
limiting step in electron transport chain. Therefore this
decrement is, in part, responsible for the observed loss in
NADH oxidase activity. Other deficits that contribute to
the diabetes-induced declines in electron transport are
under investigation.
Discussion
It has been difficult in obtaining sequential analyses of
early diabetic cardiomyopathy in humans, and even in
small animal models. The cardiac phenotype of diabetic
mice has been examined using in vivo and ex vivo tech-
niques in both type 1 and type 2 diabetic mouse models
[14-19,21-23]. In vivo evidence for cardiac dysfunction in
diabetic mice is commonly obtained from echocardiogra-
phy [15-17] and/or invasive catheterization [18,21].
Transthoracic echocardiography is a noninvasive method
for in vivo assessment of cardiac function. It is readily
Blood glucose levels in control and diabetic mice Figure 1
Blood glucose levels in control and diabetic mice. 
Mice were treated with streptozotocin (STZ) or citrate 
buffer on days 0 and 1. The onset of hyperglycemia occurred 
within one week after STZ injection. Mice were given low 
dosages of long acting insulin to maintain blood glucose at 
19–25 mmol/l. Values are mean ± SEM. Control, n = 12; dia-
betic, n = 8.
Table 1: Body weight and heart weight data from control and diabetic mice.
Control (n = 8) Diabetic (n = 12) P value
Body weight (g) 20.2 ± 0.4 17.6 ± 0.6 < 0.01
Heart weight (mg) 86.8 ± 1.2 77.3 ± 1.7 < 0.001
HW/BW ratio (mg/g) 4.3 ± 0.1 4.4 ± 0.1 NS
Values are mean ± SEM. HW/BW, heart weight to body weight ratio.Cardiovascular Diabetology 2007, 6:6 http://www.cardiab.com/content/6/1/6
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available and very useful for serial studies on age-depend-
ent cardiac changes [38,39]. M-mode echocardiography
provides indices of LV systolic function and calculated LV
mass, while Doppler measurements of transmitral flow
provide an index of diastolic function [26,40]. Systolic
and diastolic dysfunction has been demonstrated in dia-
betic mice [15-17]. However, these animals were either
severely diabetic (blood glucose of > 33 mmol/l for 3
weeks) or chronically diabetic (12 weeks). In a study of 4-
week STZ-diabetic mice, echocardiography did not reveal
a significantly reduced systolic function [19]. This may
relate to the less sensitive techniques used for systolic
function evaluation. Additionally, methods for measure-
ment of cardiac mass and volume generally depend on use
of linear measurements and calculation of mass and vol-
ume based on geometric assumptions that may or may
not be accurate for that organ.
MRI provides accurate, reproducible, noninvasive 3-
dimensional representations of cardiac structure and
function. The MRI techniques have been adapted and val-
idated to assess mouse cardiac function in vivo [24-28].
Unlike echocardiography, the 3-dimensional MR images
also provide an accurate analysis of morphological
changes without requiring geometric assumptions [26].
Our studies using this technique clearly demonstrated
that STZ-diabetic mice had ventricular wall thinning,
increased end-systolic diameter and volume, diminished
ejection fraction, decreased circumferential shortening,
and decreased peak ejection and filling rates. These
changes are consistent with those described using other in
vivo techniques at various stages in development of dia-
betic cardiomyopathy [15-18,21]. The MRI interrogation
of myocardial performance appears to offer the sensitivity
needed for the early detection of physiological events that
correlate with the onset of metabolic and other patho-
physiologic mechanisms that are etiologic in diabetic car-
diomyopathy.
In preliminary studies, we examined one marker of the
onset of mitochondrial dysfunction (NADH oxidase activ-
ity) and demonstrated this parameter was decreased by
50% at 4 weeks. This translates into a significant defi-
ciency of mitochondrial electron transport and serves as
one of several indicators of an impaired cardiac energy
state in early diabetes. These data help confirm a meta-
bolic basis for the observed impairment of cardiac func-
tion using MRI interrogation. Mitochondrial dysfunction
has been reported in the diabetic heart [41,42]. Such
reduced energy stores would lead to subsequent myocar-
dial dysfunction. Since mitochondrial ATP synthesis is the
major source of energy in cardiomyocytes, repetitive
measurement of this parameter would be of value. Future
work must establish precise molecular mechanisms by
which diabetes leads to declines in mitochondrial func-
tion and determine whether these decrements are of suffi-
Table 2: Comparison of MRI-derived LV diameter and wall thickness in control and diabetic mice.
Control (n = 8) Diabetic (n = 12) P value
Internal diameter, diastole (mm) 3.4 ± 0.1 3.6 ± 0.1 NS
Internal diameter, systole (mm) 1.8 ± 0.1 2.4 ± 0.1 < 0.001
Wall thickness, diastole (mm) 1.01 ± 0.05 0.85 ± 0.03 < 0.01
Wall thickness, systole (mm) 1.51 ± 0.06 1.19 ± 0.05 < 0.001
Values are mean ± SEM.
End-diastolic (left) and end-systolic (right) MR images in a  mid-ventricular slice from a control (top) and diabetic (bot- tom) mouse Figure 2
End-diastolic (left) and end-systolic (right) MR 
images in a mid-ventricular slice from a control (top) 
and diabetic (bottom) mouse. The LV diameters for the 
control and diabetic mouse were similar at end diastole (ED), 
but apparently increased at end systole (ES) for the diabetic 
mouse heart compared with control. The wall thickness at 
both end diastole and end systole in the diabetic mouse heart 
was decreased compared with control.Cardiovascular Diabetology 2007, 6:6 http://www.cardiab.com/content/6/1/6
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cient magnitude to limit the supply of energy for cardiac
function.
Recently, MR spectroscopy has been used in mice to exam-
ine myocardial energy metabolism [27,43]. 31P spectra
provide the only noninvasive method to quantitate myo-
cardial high-energy phosphates (ATP, phosphocreatine).
This novel technique should prove complementary to
standard MRI interrogation to study the contribution of
altered energy metabolism to the development of diabetic
cardiomyopathy. The major drawback at present is the
design of appropriate small coils that will permit accurate
localization of data to the myocardium separate from the
underlying blood.
Despite its advantages, MRI has limitations. It is costly,
time consuming, has blood flow and motion generated
artifacts, and has limited availability. Application of sen-
sitive, discriminate software to minimize manual determi-
nation of selected cardiac parameters such as cardiac
borders in repetitive slices will decrease the time required
for analysis. We have found that the time required for
positioning and acquisition of the relevant data was sig-
nificantly decreased with experience of the personnel.
Conclusion
In summary, we have implemented a noninvasive MRI
technique that was used for the first time to detect and
characterize the early onset of myocardial dysfunction in
a mouse model of type 1 diabetes. This provides a power-
ful approach to examining early cardiac dysfunction in
vivo in mice with transgenic manipulation or pharmaco-
logical interventions that will ultimately lead to a better
understanding of the pathophysiology and to reduction
of the incidence of diabetic cardiomyopathy in humans.
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Peak LV ejection and filling rates calculated from the maxi- mum slopes of the volume-time curves for control and dia- betic mice Figure 4
Peak LV ejection and filling rates calculated from the 
maximum slopes of the volume-time curves for con-
trol and diabetic mice. These data were obtained from 
the LV volume-time curve for each mouse, as shown for a 
single mouse in Figure 3. Values are mean ± SEM. *P < 0.05 
and **P < 0.01 vs. control, n = 8.
Table 3: Comparison of MRI-derived LV volume and systolic function between control and diabetic mice.
Control (n = 8) Diabetic (n = 12) P value
Heart Rate (bpm) 470 ± 11 446 ± 11 NS
End-diastolic volume (µl) 46.0 ± 1.1 44.8 ± 1.0 NS
End-systolic volume (µl) 18.3 ± 0.5 22.6 ± 0.5 < 0.001
Stroke volume (µl) 27.8 ± 0.7 22.3 ± 0.8 < 0.001
Ejection fraction (%) 60.3 ± 0.6 49.6 ± 1.3 < 0.001
Cardiac output (ml/min) 13.1 ± 0.4 9.9 ± 0.5 < 0.05
Fractional shortening (%) 37.7 ± 1.4 24.2 ± 1.6 < 0.001
Values are mean ± SEM.
LV volume-time curves from a representative control and  diabetic mouse Figure 3
LV volume-time curves from a representative con-
trol and diabetic mouse. The LV cavity slice volume in a 
mid-ventricular short-axis cine image is plotted against time 
of acquisition within the cardiac cycle. The difference of end-
systolic volumes between control and diabetic mouse is 
apparent, while the end-diastolic volumes are similar. The 
maximum ejection rate and maximum filling rate calculated 
from these curves both are decreased in diabetic mice.Cardiovascular Diabetology 2007, 6:6 http://www.cardiab.com/content/6/1/6
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Effect of diabetes on mitochondrial NADH oxidase and cit- rate synthase activity Figure 6
Effect of diabetes on mitochondrial NADH oxidase 
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M-mode echocardiographic and Doppler flow analysis on control and diabetic mice Figure 5
M-mode echocardiographic and Doppler flow analysis on control and diabetic mice. Cardiac performance was 
examined 4 weeks after onset of hyperglycemia. PWT, posterior wall thickening; AWT, anterior wall thickening; E/A, E to A 
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